Several biotech stocks maintained throughout Asco the momentum they had going into the meeting, and intrigue over Tigit continued.
The company’s Tigit data are strong enough for a phase 3 trial to be launched, Asco learns.
An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.
With Tigit out of favour Belgium’s Iteos reckons it could have the best possible PD-(L)1 combo, but does GSK share its optimism?
The second quarter promises big data reveals for Fibrogen, Travere, Argenx and Bavarian Nordic.
But two have already disappointed, and the third has shown little to suggest a positive outcome.
The Arc-7 trial might be a numerical success, but Roche’s experience will weigh heavy.